Tectonic Therapeutic Inc. (TECX)

NASDAQ: TECX · IEX Real-Time Price · USD
16.94
+0.50 (3.04%)
Jul 12, 2024, 4:30 PM EDT - Market closed
3.04%
Market Cap 249.60M
Revenue (ttm) n/a
Net Income (ttm) 30.31M
Shares Out 14.73M
EPS (ttm) 8.28
PE Ratio 2.05
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,235
Open 16.50
Previous Close 16.44
Day's Range 16.50 - 17.05
52-Week Range 1.40 - 19.80
Beta 1.22
Analysts Strong Buy
Price Target 76.00 (+348.64%)
Earnings Date Aug 24, 2024

About TECX

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trial... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2018
Employees 13
Stock Exchange NASDAQ
Ticker Symbol TECX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for TECX stock is "Strong Buy." The 12-month stock price forecast is $76.0, which is an increase of 348.64% from the latest price.

Price Target
$76.0
(348.64% upside)
Analyst Consensus: Strong Buy

News

Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer

WATERTOWN, Mass.--(BUSINESS WIRE)--Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today ann...

5 weeks ago - Business Wire

AVROBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AVROBIO, Inc. ...

2 months ago - Business Wire

AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AVROBIO, Inc. ...

5 months ago - Business Wire

Shareholder Alert: Ademi LLP investigates whether AVROBIO, Inc. has obtained a Fair Price in its transaction with Tectonic

MILWAUKEE , Jan. 31, 2024 /PRNewswire/ -- Ademi LLP is investigating AVROBIO, Inc. (Nasdaq: AVRO)  for possible breaches of fiduciary duty and other violations of law in its transaction with Tectonic....

5 months ago - PRNewsWire

AVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AVROBIO, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AVROBIO, Inc. (NASDAQ: AVRO) and Tectonic Therapeutic, Inc. is fair to AVROBIO sharehol...

5 months ago - Business Wire

AVROBIO and Tectonic Therapeutic Announce Merger

CAMBRIDGE, Mass. & WATERTOWN, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-prot...

5 months ago - Business Wire

AVROBIO to Explore Strategic Alternatives

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that...

1 year ago - Business Wire

AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the ...

1 year ago - Business Wire

AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced an a...

1 year ago - Business Wire

AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced foll...

1 year ago - Business Wire

AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported finan...

1 year ago - Business Wire

AVROBIO Announces Leadership Transition

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the ...

1 year ago - Business Wire

AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported finan...

1 year ago - Business Wire

AVROBIO to Participate in Cowen's 43rd Annual Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that...

1 year ago - Business Wire

AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc.

1 year ago - Business Wire

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the com...

1 year ago - Business Wire

AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced new interim ...

1 year ago - Business Wire

AVROBIO to Share Comprehensive Gaucher Disease Program Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will...

1 year ago - Business Wire

AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported favor...

1 year ago - Business Wire